FY2025 Earnings Estimate for KPTI Issued By Leerink Partnrs

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Stock analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for shares of Karyopharm Therapeutics in a report issued on Wednesday, February 19th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings of ($0.75) per share for the year, down from their previous estimate of ($0.66). The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.02. The firm had revenue of $30.54 million for the quarter, compared to analyst estimates of $30.29 million.

Several other research analysts also recently issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. Piper Sandler upped their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, StockNews.com cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Price Performance

Shares of Karyopharm Therapeutics stock opened at $0.57 on Monday. The firm’s fifty day simple moving average is $0.66 and its 200-day simple moving average is $0.75. Karyopharm Therapeutics has a 12 month low of $0.51 and a 12 month high of $1.70. The stock has a market capitalization of $72.07 million, a price-to-earnings ratio of -0.56 and a beta of 0.06.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Velan Capital Investment Management LP purchased a new stake in Karyopharm Therapeutics in the 4th quarter valued at approximately $27,000. Two Sigma Advisers LP boosted its stake in shares of Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after buying an additional 45,400 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of Karyopharm Therapeutics by 60.3% in the fourth quarter. Two Sigma Investments LP now owns 137,786 shares of the company’s stock valued at $93,000 after buying an additional 51,856 shares in the last quarter. Shay Capital LLC acquired a new position in Karyopharm Therapeutics during the fourth quarter worth $116,000. Finally, Focus Partners Wealth purchased a new position in Karyopharm Therapeutics in the fourth quarter worth $31,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).